Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced the pricing of an underwritten public offering of an aggregate 4,444,444 shares of its common stock and warrants to purchase an aggregate of 3,333,333 shares of the Company’s common stock at a combined price to the public of $4.50. The shares of common stock and warrants will be issued separately. On Friday shares of Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) closed at $3.77.
Oncothyreon Inc. (NASDAQ:ONTY) announced the pricing of previously announced concurrent but separate underwritten offerings of 13,500,000 shares of its Common Stock at a price to the public of $1.50 per share, for expected gross proceeds of approximately $20 million and 1,333 shares of its Series B Convertible Preferred Stock at a price to the public of $1,500 per share, for expected gross proceeds of approximately $2 million. Oncothyreon Inc (NASDAQ:ONTY) in last trading activity moved down -4.46% to close at $1.50. Company weekly performance is -5.06% while its quarterly performance stands at -11.76%. Oncothyreon Inc (NASDAQ:ONTY) is -63.24% away from its 52 week high.
On 29 January, TRACON Pharmaceuticals Inc. (NASDAQ:TCON) raised $36 million by offering 3.6 million shares at $10, well below the $12 to $14 range. On last trading day TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) moved down -0.43% to close at $9.29.
On 3 February, Enzymotec Ltd. (NASDAQ:ENZY) announced that the Australian Patent Office has issued a favorable response to the Company’s request for re-examination of Neptune Technologies & Bioressources’ (“Neptune”) patent as it relates to krill oil in Australia.Enzymotec Ltd. (NASDAQ:ENZY) institutional ownership stands at 60.90%. In last trading activity company’s stock closed at $6.18.
On 4 February, Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced that it has entered into definitive agreements with two institutional investors to purchase a total of $4.2 million of equity securities of the Company. On last trading day Cleveland BioLabs, Inc. (NASDAQ:CBLI) increased 0.32% to close at $3.16. Its volatility for the week is 9.56% while volatility for the month is 15.75%. CBLI’s sales growth for past 5 years was 12.60% and its EPS growth for past 5 years was 19.40%. Cleveland BioLabs, Inc. (NASDAQ:CBLI) monthly performance is -47.33%.